Inceptua Group, a global pharmaceutical company and service partner, and Bendalis GmbH, a German manufacturer of generic oncology drugs and special therapeutics, have signed of an exclusive clinical trial supply agreement for oncology generics. 

Inceptua will serve as the exclusive distributor of Bendalis’ products for use in clinical trials worldwide, offering clinical trial sponsors access to Brexit-safe oncology standard of care medicines produced within the EU. 

Through this agreement, Inceptua adds to its range of oncology comparators and standard of care medicine it supplies for clinical trial use with exclusive access to Bendalis’ portfolio of products that are commonly used in chemotherapy, including: carboplatin, docetaxel, gemcitabine, paclitaxel, oxaliplatin, vinorelbine, irinotecan, and fluorouracil (5FU). 

“With this agreement Bendalis and Inceptua join forces to ensure optimal sourcing and supply of medicines for use in oncology clinical trials to our clients. Together, we share a mission to provide uninterrupted access for patients to high quality products through a secure and robust supply chain,” said Alan Raffensperger, chief executive officer, Inceptua Group.

“In the oncology space we experience a growing need and demand for products. We see Inceptua as the ideal partner to handle the distribution and help optimize the clinical trial supply for clients. A consistent and secure supply of products is a critical component in clinical trials, and together we can offer a flexible yet reliable solution, helping clients minimize overage and reduce costs,” says Christian Parvany, chief executive officer, Bendalis.